SEC Form SC 13G/A filed by Guardant Health Inc. (Amendment)

3/10/23 9:30:09 AM ET

Medical Specialities

Health Care

Get the next $GH alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 GUARDANT HEALTH INC COMMON STOCK Cusip #40131M109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #40131M109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,864,071 Item 6: 0 Item 7: 8,933,365 Item 8: 0 Item 9: 8,933,365 Item 11: 8.695% Item 12: HC Cusip #40131M109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 8,933,365 Item 8: 0 Item 9: 8,933,365 Item 11: 8.695% Item 12: IN Item 1(a). Name of Issuer: GUARDANT HEALTH INC Item 1(b). Address of Issuer's Principal Executive Offices: 3100 HANOVER STREET PALO ALTO, CA 94304 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 40131M109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 8,933,365 (b) Percent of Class: 8.695% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 8,933,365 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of GUARDANT HEALTH INC. No one other person's interest in the COMMON STOCK of GUARDANT HEALTH INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on March 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of GUARDANT HEALTH INC at February 28, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $GH alert in real time by email

Recent Analyst Ratings for

$GH

Date	Price Target	Rating	Analyst
4/10/2025	$55.00	Outperform	Mizuho
1/23/2025	$60.00	Overweight	Barclays
6/28/2024	$36.00	Neutral → Buy	Guggenheim
6/3/2024	$32.00	Buy	Jefferies
4/24/2024	$28.00	Buy	Craig Hallum
12/14/2023		Neutral	Guggenheim
12/13/2023		Peer Perform	Wolfe Research
11/13/2023	$27.00	Mkt Perform → Outperform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by Guardant Health Inc. (Amendment)

3/10/23 9:30:09 AM ET

$GH

Medical Specialities

Health Care

Get the next $GH alert in real time by email

Recent Analyst Ratings for

$GH

Date	Price Target	Rating	Analyst
4/10/2025	$55.00	Outperform	Mizuho
1/23/2025	$60.00	Overweight	Barclays
6/28/2024	$36.00	Neutral → Buy	Guggenheim
6/3/2024	$32.00	Buy	Jefferies
4/24/2024	$28.00	Buy	Craig Hallum
12/14/2023		Neutral	Guggenheim
12/13/2023		Peer Perform	Wolfe Research
11/13/2023	$27.00	Mkt Perform → Outperform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by Guardant Health Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $GH

SEC Form SC 13G/A filed by Guardant Health Inc. (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $GH

$GH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

$GH Press Releases

Fastest customizable press release news feed in the world

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

$GH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Joyce Meghan V. converted options into 66 shares, increasing direct ownership by 0.59% to 11,216 units (SEC Form 4)

Chief Legal Officer Saia John G. converted options into 2,641 shares and covered exercise/tax liability with 1,386 shares, increasing direct ownership by 3% to 44,823 units (SEC Form 4)

Chief Information Officer Kalia Kumud converted options into 2,691 shares and covered exercise/tax liability with 1,365 shares, increasing direct ownership by 7% to 20,500 units (SEC Form 4)

$GH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

July 30, 2024 - FDA Roundup: July 30, 2024

May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

$GH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Mizuho initiated coverage on Guardant Health with a new price target

Barclays initiated coverage on Guardant Health with a new price target

Guardant Health upgraded by Guggenheim with a new price target

$GH SEC Filings

SEC Form 8-K filed by Guardant Health Inc.

SEC Form 144 filed by Guardant Health Inc.

SEC Form 144 filed by Guardant Health Inc.

$GH Financials

Live finance-specific insights

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

$GH Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Guardant Health Inc.

SEC Form SC 13G filed by Guardant Health Inc.

Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

$GH Leadership Updates

Live Leadership Updates

Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

Roberto A. Mignone Joins Guardant Health Board of Directors

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

Recent Analyst Ratings for
$GH

Recent Analyst Ratings for
$GH

$GH
Insider Purchases

$GH
Press Releases

$GH
Insider Trading

$GH
FDA approvals

$GH
Analyst Ratings

$GH
SEC Filings

$GH
Financials

$GH
Large Ownership Changes

$GH
Leadership Updates